WhaleCreep

RA Capital Management, L.P. 13F holdings, Q1 2015

Hedge fundSEC filingsCompare with another fundHoldings as of 2015-03-31, filed 2015-07-06

RA Capital Management, L.P. disclosed 56 US equity positions worth $912.9m in its Q1 2015 13F filing. Its largest position is ACHNEUR at 8.9% of the reported book, followed by DYAX CORP and BCRX. Versus Q4 2014 it opened 12 new positions, added to 4, reduced 12 and exited 4.

$913m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
56
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
8.9%
Largest position
The largest single position as a share of the reported equity book.
62.2%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
21
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
73
Quarters on file since Q4 2007
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2014: 12 new, 4 added, 12 reduced, 4 exited

50 of 56
ACHNEUR ACHILLION PHARMACEUTICALS IN–8.9%$80.9m8.21m+23%added
DYAX CORP no ticker–7.7%$70.5m4.21m−15%reduced
BCRX BIOCRYST PHARMACEUTICALS INCHealthcare6.9%$62.5m6.93m−1.8%reduced
REGULUS THERAPEUTICS INC no ticker–6.7%$60.8m3.59m−24%reduced
DRNAUSD DICERNA PHARMACEUTICALS INC–6.4%$58.4m2.43m0.0%held
DVAX DYNAVAX TECHNOLOGIES CORP–6.4%$58.3m2.60m–new
TGTX TG THERAPEUTICS INCHealthcare5.3%$48.4m3.13m−6.7%reduced
CHRS COHERUS ONCOLOGY INCHealthcare5.2%$47.6m1.56m0.0%held
TEKMIRA PHARMACEUTICALS CORP no ticker–5.2%$47.4m2.71m–new
XNCR XENCOR INCHealthcare3.6%$32.9m2.15m+54%added
ZFGNUSD ZAFGEN INC–3.2%$29.0m732,9600.0%held
BLUEBIRD BIO INC no ticker–2.7%$24.2m200,379−60%reduced
BELLICUM PHARMACEUTICALS INC no ticker–2.6%$23.8m1.03m0.0%held
ZS PHARMA INC no ticker–2.6%$23.8m564,4830.0%held
SGMOQ SANGAMO THERAPEUTICS INCHealthcare2.1%$19.1m1.22m0.0%held
ASND ASCENDIS PHARMA A/SHealthcare1.9%$17.8m1.02m–new
JUNO THERAPEUTICS INC no ticker–1.9%$17.0m280,0000.0%held
OMER OMEROS CORPHealthcare1.8%$16.5m749,000–new
PRTOEUR PROTEON THERAPEUTICS INC–1.6%$14.5m1.25m0.0%held
AGRXUSD AGILE THERAPEUTICS INC–1.5%$13.5m1.46m–new
NVAX NOVAVAX INCHealthcare1.3%$11.8m1.43m−56%reduced
TXMD THERAPEUTICSMD INCHealthcare1.1%$10.2m1.68m−48%reduced
ARRYEUR ARRAY BIOPHARMA INC–1.1%$10.0m1.36m–new
CNCEEUR CONCERT PHARMACEUTICALS INC–1.1%$10.0m660,000–new
OREXIGEN THERAPEUTICS INC no ticker–1.0%$9.3m1.19m–new
TENX TENAX THERAPEUTICS INC–1.0%$8.7m2.67m0.0%held
TREVENA INC no ticker–0.9%$8.6m1.33m−55%reduced
SUCAMPO PHARMACEUTICALS INC no ticker–0.8%$7.0m450,000–new
VICAL INC no ticker–0.7%$6.6m7.02m+13%added
AKBA AKEBIA THERAPEUTICS INCHealthcare0.7%$6.6m597,3630.0%held
AUPH AURINIA PHARMACEUTICALS INCHealthcare0.7%$6.6m1.50m−39%reduced
SCYX SCYNEXIS INC–0.7%$6.5m789,097−6.1%reduced
AURIS MED HLDG AG no ticker–0.6%$5.0m940,0000.0%held
VERSARTIS INC no ticker–0.5%$4.2m231,2670.0%held
TROVAGENE INC no ticker–0.4%$4.0m594,200–new
BIOTA PHARMACEUTIALS INC no ticker–0.4%$3.2m1.40m+1.8%added
ROCKWELL MED INC no ticker–0.3%$2.7m250,207−65%reduced
T2 BIOSYSTEMS INC no ticker–0.2%$2.1m138,0020.0%held
OCERA THERAPEUTICS INC no ticker–0.2%$2.0m417,4760.0%held
ONCOTHYREON INC no ticker–0.2%$1.9m1.17m–new
AGIO AGIOS PHARMACEUTICALS INCHealthcare0.2%$1.7m17,6000.0%held
NLNKEUR NEWLINK GENETICS CORP–0.2%$1.6m30,0000.0%held
PTCT PTC THERAPEUTICS INCHealthcare0.2%$1.6m25,8000.0%held
MERRIMACK PHARMACEUTICALS IN no ticker–0.2%$1.4m116,4000.0%held
RGEN REPLIGEN CORPHealthcare0.1%$1.4m45,0000.0%held
T8S TESARO INC–0.1%$1.3m23,500–new
ALKS ALKERMES PLCHealthcare0.1%$1.2m19,2000.0%held
WAFERGEN BIO-SYSTEMS INC no ticker–0.1%$1.2m255,400−54%reduced
REGN REGENERON PHARMACEUTICALSHealthcare0.1%$1.1m2,4500.0%held
BIIB BIOGEN INCHealthcare0.1%$1.1m2,6000.0%held

Exited since Q4 2014

4 rows
FORWARD PHARMA A/S no ticker2.6%$20.2m
OPHTHOTECH CORP no ticker1.8%$13.9m
CTI BIOPHARMA CORP no ticker0.8%$5.9m
KYTHERA BIOPHARMACEUTICALS I no ticker0.1%$789k

Sector mix

  • Unclassified68.2%
  • Healthcare31.8%

Book over time

Every quarter on file (73)
QuarterPositionsEquity book
Q2 202684$11.5bn
Q1 202685$9.4bn
Q4 202571$9.8bn
Q3 202567$8.1bn
Q2 202563$5.9bn
Q1 202585$6.0bn
Q4 202489$7.5bn
Q3 202481$8.7bn
Q2 202478$7.6bn
Q1 202476$7.9bn
Q4 202362$6.4bn
Q3 202366$5.1bn
Q2 202354$5.3bn
Q1 202359$4.4bn
Q4 202270$4.9bn
Q3 202281$4.7bn
Q2 202288$3.8bn
Q1 202296$4.6bn
Q4 202197$5.7bn
Q3 202195$7.2bn
Q2 202192$6.2bn
Q1 202182$6.6bn
Q4 202082$7.2bn
Q3 202070$5.5bn
Q2 202057$5.1bn
Q1 202048$3.2bn
Q4 201934$3.3bn
Q3 201932$1.7bn
Q2 201925$1.9bn
Q1 201929$2.3bn
Q4 201825$1.7bn
Q3 201826$1.9bn
Q2 201827$1.5bn
Q1 201831$1.3bn
Q4 201727$1.2bn
Q3 201727$1.1bn
Q2 201722$871m
Q1 201724$815m
Q4 201627$706m
Q3 201630$969m
Q2 201632$722m
Q1 201642$782m
Q4 201537$1.0bn
Q3 201547$696m
Q2 201558$928m
Q1 201556$913m
Q4 201448$777m
Q3 201443$622m
Q2 201424$756m
Q1 201429$973m
Q4 201324$648m
Q3 201331$724m
Q2 201325$616m
Q1 201317$407m
Q4 201219$225m
Q3 201221$198m
Q2 201226$223m
Q1 201223$185m
Q4 201118$124m
Q3 201120$90.3m
Q2 201120$108m
Q1 201121$130m
Q4 201016$101m
Q3 201018$101m
Q1 201021$102m
Q4 200914$75.1m
Q2 200916$107m
Q1 200912$184m
Q4 20088$224m
Q3 200820$329m
Q2 200822$220m
Q1 200817$135m
Q4 200723$159m

Where RA Capital Management, L.P. was early

110 rows
VRTX VERTEX PHARMACEUTICALS INCQ1 20082 of 16012.5%12.5%7Exited by Q4 2014+370%
AMAG AMAG PHARMACEUTICALS INCQ2 20081 of 693.4%9.2%7Exited by Q3 2010+2.4%
GILD GILEAD SCIENCES INCQ4 20087 of 1810.7%15.8%6Exited by Q2 2020+192%
BSTC BIOSPECIFICS TECHNOLOGIES COQ1 20091 of 299.0%32.9%7Exited by Q3 2011–
ALXN ALEXION PHARMACEUTICALS INCQ2 20092 of 1476.6%9.6%5Exited by Q2 2011–
UTHR UNITED THERAPEUTICS CORP DELQ2 20092 of 1617.0%7.0%5Exited by Q2 2011+61%
ENZB ENZO BIOCHEM INCQ1 20101 of 400.6%3.9%7Exited by Q1 2014–
ACAD ACADIA PHARMACEUTICALS INCQ1 20111 of 1456.5%21.1%17Exited by Q3 2015+2485%
NVAX NOVAVAX INCQ4 20111 of 1171.0%14.4%24Exited by Q2 2022+192%
SGMOQ SANGAMO THERAPEUTICS INCQ4 20111 of 852.0%13.6%22Exited by Q4 2017+428%
BCRX BIOCRYST PHARMACEUTICALS INCQ1 20121 of 1218.0%11.1%28Held at last filing, Q2 2026+107%
VSTM VERASTEM INCQ1 20121 of 1003.6%3.6%6Exited by Q4 2020−89%
IMMU IMMUNOMEDICS INCQ1 201311 of 1110.6%4.8%6Exited by Q1 2019+492%
ENTA ENANTA PHARMACEUTICALS INCQ2 20131 of 921.3%8.8%8Exited by Q1 2025−68%
INSM INSMED INCQ2 20131 of 1804.7%6.4%9Exited by Q2 2025+538%
OMER OMEROS CORPQ2 20131 of 662.4%2.4%4Exited by Q3 2015+257%
PRTA PROTHENA CORP PLCQ2 20131 of 1011.0%6.7%4Exited by Q2 2014+197%
TXMD THERAPEUTICSMD INCQ2 20131 of 655.5%9.4%13Exited by Q3 2021−61%
PTCT PTC THERAPEUTICS INCQ3 20131 of 1270.9%2.6%7Exited by Q3 2015+124%
TGTX TG THERAPEUTICS INCQ3 20131 of 1140.4%6.8%30Exited by Q1 2022+277%
T8S TESARO INCQ4 20131 of 833.1%3.1%4Exited by Q3 2015+108%
XNCR XENCOR INCQ4 20131 of 1023.8%3.8%13Held at last filing, Q2 2026+76%
MGNX MACROGENICS INCQ4 201310 of 1040.8%2.6%16Held at last filing, Q2 2026−83%
SCYX SCYNEXIS INCQ2 20141 of 470.9%1.1%4Exited by Q2 2015+3.5%
AKBA AKEBIA THERAPEUTICS INCQ2 20142 of 1032.2%2.2%5Exited by Q3 2017−48%
TENX TENAX THERAPEUTICS INCQ3 20143 of 561.5%1.5%10Exited by Q1 2017−50%
CHRS COHERUS BIOSCIENCES INCQ4 20141 of 1053.3%5.2%6Exited by Q2 2016+30%
AUPH AURINIA PHARMACEUTICALS INCQ4 20142 of 1001.2%1.2%3Exited by Q3 2015−17%
ASND ASCENDIS PHARMA A/SQ1 20151 of 1371.9%29.9%46Held at last filing, Q2 2026+1437%
DVAX DYNAVAX TECHNOLOGIES CORPQ1 20151 of 1166.4%6.4%4Exited by Q1 2020−75%
2655787D BLUEPRINT MEDICINES CORPQ2 20151 of 1472.5%2.7%4Exited by Q2 2016−32%
COLL COLLEGIUM PHARMACEUTICAL INCQ2 20151 of 963.0%4.9%4Exited by Q2 2016+1.7%
MCRB SERES THERAPEUTICS INCQ2 20151 of 751.1%2.5%5Exited by Q3 2021−43%
ARDX ARDELYX INCQ2 20152 of 1143.0%4.4%15Exited by Q3 2021−53%
AIMT AIMMUNE THERAPEUTICS INCQ3 20151 of 742.9%2.9%6Exited by Q1 2017−19%
NTRA NATERA INCQ3 20151 of 1671.2%1.3%6Exited by Q3 2022+227%
ACRS ACLARIS THERAPEUTICS INCQ4 20151 of 1146.8%6.8%15Held at last filing, Q2 2026−80%
WVE WAVE LIFE SCIENCES LTDQ4 20151 of 12311.2%26.3%43Held at last filing, Q2 2026−64%
ONC BEIGENE LTDQ1 20164 of 1040.6%1.1%5Exited by Q2 2017+25%
NKTR NEKTAR THERAPEUTICSQ1 20165 of 1455.6%6.5%4Exited by Q4 2023−96%
PTGX PROTAGONIST THERAPEUTICS INCQ3 20162 of 1361.6%2.1%3Exited by Q2 2017−39%
4XC1 KALVISTA PHARMACEUTICALS INCQ4 20161 of 910.6%1.8%15Exited by Q2 2022+108%
KDMN KADMON HLDGS INCQ3 20173 of 762.0%2.0%2Exited by Q1 2018+8.1%
SCPH SCPHARMACEUTICALS INCQ4 20171 of 642.9%2.9%19Exited by Q1 2023−41%
SPRO SPERO THERAPEUTICS INCQ4 20171 of 441.2%1.2%3Exited by Q3 2018+25%
IFRX INFLARX NVQ4 20172 of 575.0%5.0%8Exited by Q4 2025−94%
SG7 SAGE THERAPEUTICS INCQ4 201714 of 1326.3%6.3%5Exited by Q2 2019−3.4%
SLDB SOLID BIOSCIENCES INCQ1 20181 of 951.5%6.8%34Held at last filing, Q2 2026−91%
IOVA IOVANCE BIOTHERAPEUTICS INCQ1 20186 of 1300.9%1.4%5Exited by Q2 2019−44%
RYTM RHYTHM PHARMACEUTICALS INCQ2 20183 of 1143.1%7.3%33Held at last filing, Q2 2026+255%

Concentration and tenure

18.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
70.5%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters